Exosens shares decline 3.5%, among the largest falls in the SBF 120

Exosens among the largest declines in the SBF 120, following a target price increase by Bernstein

The Exosens share is down 3.71% to €61.05 in trading, ranking among the largest declines in the SBF 120 this Thursday. The pullback contrasts with the target increase carried out on September 23 by Bernstein, which raised its objective from €71.50 to €74, while maintaining its "outperform" rating. Relative to the current price of €61.05, this target represents an upside potential of approximately 21%.

The trading session context is weighing: the CAC 40 is down 0.8% and the SBF 120 is declining proportionally, in an environment unfavorable to risky assets while bond yields remain under pressure. Despite today's pullback, Exosens is maintaining a gain of 12.33% over the week, extending the momentum initiated following the upward revision of its annual targets on September 17.

Above its three moving averages, the stock maintains a positive technical configuration despite today's pressure

Despite this session's pullback, the chart configuration remains favorable in the medium term. The stock is trading above its three moving averages: MA20 at €57.82 (spread of +5.59%), MA50 at €59.76 (+2.16%) and MA200 at €59.25 (+3.04%). These three levels thus form a natural technical floor in the €57 to €60 zone.

The RSI at 64 reflects buying momentum still present, without reaching the overbought zone. The support identified at €54.15 remains far from the current price, while the resistance at €66.80 represents the next level to overcome to extend the bullish movement of recent weeks. The publication of nine-month results, expected on October 27 according to the annual targets communicated on September 17, will constitute the next benchmark for measuring the group's growth trajectory.